2/ About the co. - Great export biz - almost 50% Revenue from sales in 60+ countries (Exports). No client concentration risk with top 10 making 23% sales only.
3/ Leading forward integrated domestic producer of Synthetic pyrethroids & has has presence across its value chain (intermediates, technicals & formulations).
4/ Growth strategy - Entering the highly regulated USA and EU market got me excited along with other growth levers.
5/ But then it occurred to me what are Pyrethroids ? Here's where I started searching internet and this become my biggest Anti-Thesis point.
6/ Pyrethroids are less acutely toxic than organophosphate pesticides, but are associated with neurological disorders in humans and are harmful to pollinators and fish (remember this).
U.S Environmental Protection Agency (EPA) is the authorized body which publishes guidelines and regulations impacting the Agrochemicals among other environmental aspects.
8/ Before introducing Pyrethroids more of Organophosphate based insecticides were in use but as more & more research provided evidence of its major health hazards EPA started banning the products.
Organophosphate pesticides are being replaced by these now & what ever little research done so far there are signs that it isn't really the best replacement and is causing health issues among other hazards.
10/ Reading this article gives you a sense of the corruption in the approval & testing phase. The authorized officer waived toxicity test for pyrethroids when concerns were raised and then joined a private co. that made the product.
11/ Came across several other articles as well talking about the toxicity of Pyrethroids.
Now, assuming more research takes place giving further evidences of its health hazards and with mounting pressure from the environmental groups.
12/ There is regulatory risk that EPA may start banning these products as well. This could be further pushed with the adoption of much safer substitutes.
How long it'll take and when that may happen is the Million Dollar question. I may just stay away due to hazardous nature.
13/ Now, what impact could this have on a co. like Hiranba ?
Well, >60% revenue comes from Pyrethroids.
Highly concentrated !!!
14/ Reading this I feel with the current focus on health, clean chemicals & ESG. I may want to avoid this risk although I may be extrapolating the extent.
But can't deny that this risk exists.
Also, coz I have enough regulatory risk facing pharma businesses in PF- Risk Appetite
15/ With this exercise I think I'll be more thoughtful of the products that a chemical company manufactures and its environmental risks.
Let me know what do you think about this regulatory risk.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
#EMS market is set to grow at +30% CAGR for at least next 5 years from ₹1,469Bn to ₹6,000Bn by FY27.
🧵 on some spl. business insights from Q3FY23 concall & other sources
@soicfinance @ishmohit1
1 can't miss this decadal opp.
Retweet♻️ & Like👍
There are 2 models that business generally follow:
1. Low Value High Mix (LVHM) - eg. consumer 2. High Value Low Mix (HVLM) - eg. Industrial
This data suggests both type of businesses are set for long-term high growth.
This is a crowded space with Indian and large MNC players. However, the industry as a whole is set to grow exponentially and established players who can achieve scale & offer wider capabilities stand to win bigger + mgt. are saying they are just scratching the surface ryt now.
Interesting development: Partnered with #Foxconn in 2W EV
- Foxconn is a large key component supplier to many OEMs globally
- Focus is mass production
- Achieve economies of scale = cheaper production cost per unit
- Fully integrated solutions
So why is this imp ?🧵
1/10
2/
2021 news - Foxconn aims to build EV factories in Europe and India by 2024. Not sure if there has been any developments on ground but it gives an indication towards their ambition
Longtime iPhone assembler Foxconn has been stepping up efforts to expand its presence in the booming EV industry since its new chairman assumed position in mid 2019.
Their chairman was in India last year discussing opportunity in India.
- Business overview
- Financials
- Valuations
- 1 year Concall highlights (Q1 FY22 to Q1FY23)
Took long to compile this
Retweet♻️ & Like👍
For wider reach
@soicfinance @itsTarH @Shubham_TLI @ValueEducator @Gautam__Baid
1/14
2/ Co. overview
3/ Segments:
APIs & Intermediates for innovators & generic firms for a variety of applications like anti-cancer, anti-asthmatic, antihypertensive, oncology medicines.
Xanthine derivatives are used for beverages, as well as nutraceutical and other pharma applications.
But when your mentor asks you to read a business you oblige. Thanks @ishmohit1, please add your insights if you find any gaps.
#Taskus 🇺🇸 $TASK
"Outsourcing reimagined for the innovation age"
🔥60% Revenue CAGR over past 4 years
2/ Background: Founded in 2008 during recession by 2 high school best friends, Jasper Weir & Bryce Maddock
3/ While all major competitors in the industry were occupied serving traditional telco clients, they focused efforts on the emerging digital economy. Most clients have 3 things in common: they are truly customer obsessed, they've grown faster than nearly every other company